Landmark Phase III Study of Bayer's Xarelto® (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery Disease
•20,000-patient study will be conducted in collaboration with Population Health Research Institute •Composite of cardiovascular death, myocardial infarction and stroke as primary efficacy endpoint •Rivaroxaban is the first novel oral anticoagulant under assessment in this high risk patient population
Bayer HealthCare announced today the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto® (rivaroxaban) to date, investigating the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD).
Social Media Tools:
Click asset titles for downloads, embeds and more...
Subscribe via RSS
Journalists who register may create email subscriptions to search results and a cart of assets to download. Click here to login, register or edit profile.
What Our Users
"I like the way the DC is easy to navigate, easy to find stories, easy to find when they were filed so you know if they’re out of date, and easy to see an on-line version of the available video" -- Allan C Lee, Director of News and Current Affairs